CD133-positive circulating tumor cells (CTCs) combined with elevated CEA levels (≥5 ng/mL) were identified in 0 of 44 stage I cases, 11 of 64 stage II cases, 6 of 54 stage III cases, and 3 of 33 stage IV cases. This evidence concerns the gene CEACAM5 and neoplasm.